LEAWOOD, Kan., Dec. 15, 2017 /PRNewswire/ — Aratana Therapeutics, Inc. (NASDAQ: PETX) has received top-line pivotal field effectiveness study results for AT-016, an investigational adipose-derived allogeneic stem cell therapeutic candidate for the control of clinical signs associated…
